PhaseII study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000005690
- Lead Sponsor
- Division of Thoracic Oncology, Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Impossible cases with protcol defined oral administration. 2) Patients with symptomatic brain metastasis. 3) With active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis. 4) Thoracic radiation, within 4 weeks, irradiation to other organs within 2 weeks. 5) Uncontrollable pleural or pericardial effusion. 6) Operation within 4 weeks. 7) Active infection. 8) Active concomitant malignancy. 9) Severe drug allergy. 10) Pregnant or breast-feeding woman. 11) Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 6 months progression free survival rate
- Secondary Outcome Measures
Name Time Method Overall survival Response rate Progression free survival Adverse events